AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 28 April 2008
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01398-07v1
52/7/2647    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Krause, K. M.
Right arrow Articles by Benton, B. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krause, K. M.
Right arrow Articles by Benton, B. M.
Antimicrob. Agents Chemother. doi:10.1128/AAC.01398-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria

Kevin M. Krause, Marika Renelli, Stacey Difuntorum, Terry X. Wu, Dmitri V. Debabov, and Bret M. Benton*

Theravance, Inc., South San Francisco, CA 94080

* To whom correspondence should be addressed. Email: bbenton{at}theravance.com.


  Abstract

The in vitro activity of telavancin was tested against 743 predominantly antimicrobial-resistant Gram-positive isolates. Telavancin was highly active against methicillin-resistant staphylococci (MIC90, 0.5 - 1 µg/mL) streptococci (all MICs, ≤0.12 µg/mL) and VanB-type enterococci (all MICs, ≤4 µg/mL). Time-kill studies demonstrated the potent bactericidal activity of telavancin.




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.